公开(公告)号：US20040266711A1

公开(公告)日：2004-12-30

申请号：US10795078

申请日：2004-03-03

申请人： Pharming B.V.

发明人： Jeffrey M. Rosen

IPC分类号： A61K048/00 ,  A01K067/00

CPC分类号： A01K67/0275 ,  A01K67/02 ,  A01K2217/05 ,  A01K2217/20 ,  A01K2227/10 ,  A01K2227/105 ,  A01K2267/01 ,  A23C9/20 ,  A23C2230/05 ,  C07K14/4732 ,  C07K2319/00 ,  C07K2319/02 ,  C07K2319/61 ,  C12N9/1033 ,  C12N15/63 ,  C12N15/85 ,  C12N15/8509 ,  C12N15/89 ,  C12N2830/008 ,  C12N2830/30 ,  C12N2830/85

摘要： Described is a method of targeting specific genes to the mammary gland which results in the efficient synthesis and secretion of biologically important molecules. Further, there is described as a composition of matter, a transgenic mammal having the ability to reproduce itself and being suitable for the secretion of biologically active agents into its milk. Additionally there is disclosed as a composition of matter, recombinant DNA gene complexes designed to integrate into a mammalian genome and to synthesize and secrete biological active agents into the milk. Furthermore, methods of producing and using altered milk are disclosed.

摘要翻译： 描述了一种靶向乳腺特异性基因的方法，其导致生物重要分子的有效合成和分泌。 此外，描述为物质组合物，转基因哺乳动物具有自身繁殖并适于将生物活性剂分泌到其乳中的能力。 另外公开了一种物质组合物，设计用于整合到哺乳动物基因组中并将生物活性剂合成并分泌到乳中的重组DNA基因复合物。 此外，公开了生产和使用改性牛奶的方法。

公开(公告)号：US20040266708A1

公开(公告)日：2004-12-30

申请号：US10644288

申请日：2003-08-20

发明人： Paul Diamond

IPC分类号： A01K067/00 ,  C12N015/85 ,  A61K048/00

CPC分类号： C12N15/113 ,  C12N2310/111 ,  C12N2310/14 ,  C12N2330/30

摘要： The invention provides methods and systems for controlling the expression and, in general, the cellular activity of preselected polynucleic acid molecules. The invention also provides methods and systems for genetically modifying cells and multi-cellular organisms to impart resistance to viruses. The invention further provides methods and systems for genetically modifying cells and multi-cellular organisms so that they diagnostically report viral infection. One aspect of the invention involves rendering target polynucleic nucleic acid molecules as functional templates for at least one template-directed polynucleic acid polymerase so that utilization of the polynucleic acid molecule as a template by the polymerase modulates the activity of the targeted polynucleic acid molecule. Other aspects of the invention of the invention involve rendering selected polynucleic nucleic acid molecules as targets for RNA silencing, whether or not the silencing is polymerase-mediated.

摘要翻译： 本发明提供了用于控制预选的多核酸分子的表达和一般的细胞活性的方法和系统。 本发明还提供用于遗传修饰细胞和多细胞生物以赋予对病毒抗性的方法和系统。 本发明还提供用于遗传修饰细胞和多细胞生物体的方法和系统，使得它们诊断性地报告病毒感染。 本发明的一个方面涉及使目标多核核酸分子作为至少一个模板指导的多核酸聚合酶的功能模板，使得通过聚合酶利用聚核酸分子作为模板来调节靶向多核酸分子的活性。 本发明的其它方面涉及将选择的多核核酸分子作为RNA沉默的靶标，无论沉默是否是聚合酶介导的。

公开(公告)号：US20040255342A1

公开(公告)日：2004-12-16

申请号：US10852973

申请日：2004-05-25

申请人： EnVivo Pharmaceuticals, Inc.

发明人： David A. Lowe ,  Gerhard Koenig ,  Christopher J. Cummings

IPC分类号： G01N033/00 ,  A01K067/00 ,  A01K067/033

CPC分类号： C12N15/8509 ,  A01K67/0339 ,  A01K2217/05 ,  A01K2227/706 ,  A01K2267/0312

摘要： The present invention discloses a transgenic fly that expresses the Iowa mutant version of the human Anull42 peptide of human amyloid-null precursor protein (APP), and a double transgenic fly that expresses both the Tau protein and the human Anull42Iowa peptide of human amyloid-null precursor protein (APP). The transgenic flies of the present invention provide for models of neurodegenerative disorders, such as Alzheimer's disease. The invention further discloses methods for identifying genetic modifiers, as well as screening methods to identify therapeutic compounds to treat neurodegenerative disorders using the transgenic flies.

摘要翻译： 本发明公开了表达人淀粉样蛋白-β前体蛋白（APP）的人Aβ42肽的爱荷华突变体版本的转基因飞行物，以及表达人淀粉样蛋白-β的Tau蛋白和人Abeta42Iowa肽的双转基因蝇 前体蛋白（APP）。 本发明的转基因苍蝇提供了神经变性疾病如阿尔茨海默氏病的模型。 本发明进一步公开了用于鉴定遗传修饰剂的方法，以及用于鉴定使用转基因苍蝇治疗神经变性疾病的治疗化合物的筛选方法。

公开(公告)号：US20040244065A1

公开(公告)日：2004-12-02

申请号：US10783534

申请日：2004-02-20

发明人： David Alan Mead ,  Ronald Godiska

IPC分类号： A01K067/00 ,  C12N015/87

CPC分类号： C12N15/64 ,  C12N15/66

摘要： The present invention relates to systems, methods, and compositions for cloning and sequencing insert nucleic acid sequences. In particular, the present invention provides vectors and vector components configured for multiplex cloning, multiplex sequencing, and fixed orientation cloning. The present invention also provides vectors and vector components that allow insert sequences that are deleterious to a host cell to be successfully cloned.

公开(公告)号：US20040235011A1

公开(公告)日：2004-11-25

申请号：US10746943

申请日：2003-12-24

发明人： Richard K. Cooper ,  William C. Fioretti ,  Gary G. Cadd

IPC分类号： C12Q001/68 ,  A01K067/00 ,  C07H021/04 ,  C12P021/04

CPC分类号： C07K14/62 ,  A01K67/0275 ,  A01K2217/05 ,  A01K2227/105 ,  A01K2227/30 ,  A01K2267/01 ,  A23L15/00 ,  A23V2002/00 ,  A61K39/00 ,  A61K48/00 ,  A61K2039/505 ,  C07K16/00 ,  C07K16/02 ,  C07K16/1063 ,  C07K16/26 ,  C07K2317/23 ,  C12N15/85 ,  C12N15/8509 ,  C12N2800/90 ,  C12N2830/003 ,  C12N2830/008 ,  C12N2830/90 ,  C12N2840/20 ,  A23V2300/21

摘要： The present invention provides a new, effective and efficient method of producing multimeric proteins in an individual. Multimeric proteins include associated multimeric proteins (two or more associated polypeptides) and multivalent multimeric proteins (a single polypeptide encoded by more than one gene of interest). Expression and/or formation of the multimeric protein in the individual is achieved by administering a polynucleotide cassette containing genes of interest that encode portions of the multimeric protein to the individual. The polynucleotide cassette may additionally contain one or more pro sequences, prepro sequences, cecropin prepro sequences, and/or cleavage site sequences.

摘要翻译： 本发明提供了在个体中产生多聚体蛋白质的新的，有效的和有效的方法。 多聚体蛋白包括相关的多聚体蛋白（两个或更多个相关多肽）和多价多聚体蛋白（由多于一个感兴趣的基因编码的单个多肽）。 个体中多聚体蛋白的表达和/或形成是通过向个体施用含有编码多聚体蛋白部分的感兴趣的基因的多核苷酸盒来实现的。 多核苷酸盒可另外含有一个或多个前序列，前序列，天蚕素前序列和/或切割位点序列。

公开(公告)号：US20040231005A1

公开(公告)日：2004-11-18

申请号：US10767308

申请日：2004-01-29

申请人： Millennium Pharmaceuticals, Inc.

发明人： Rosana Kapeller-Libermann ,  David White ,  Kyle J. MacBeth

IPC分类号： A01K067/00 ,  C07H021/04 ,  C12N009/64

CPC分类号： C12N9/48

摘要： The present invention relates to a newly identified human aminopeptidase. The invention also relates to polynucleotides encoding the aminopeptidase. The invention further relates to methods using the aminopeptidase polypeptides and polynucleotides as a target for diagnosis and treatment in aminopeptidase-related disorders. The invention further relates to drug-screening methods using the aminopeptidase polypeptides and polynucleotides to identify agonists and antagonists for diagnosis and treatment. The invention further encompasses agonists and antagonists based on the aminopeptidase polypeptides and polynucleotides. The invention further relates to procedures for producing the aminopeptidase polypeptides and polynucleotides.

摘要翻译： 本发明涉及新鉴定的人类氨基肽酶。 本发明还涉及编码氨基肽酶的多核苷酸。 本发明还涉及使用氨基肽酶多肽和多核苷酸作为在氨基肽酶相关疾病中进行诊断和治疗的靶标的方法。 本发明还涉及使用氨基肽酶多肽和多核苷酸鉴定用于诊断和治疗的激动剂和拮抗剂的药物筛选方法。 本发明还包括基于氨基肽酶多肽和多核苷酸的激动剂和拮抗剂。 本发明还涉及生产氨基肽酶多肽和多核苷酸的方法。

公开(公告)号：US20040226054A1

公开(公告)日：2004-11-11

申请号：US10746473

申请日：2003-12-23

发明人： Kate Dora Games ,  Dale Bernard Schenk ,  Lisa Claire McConlogue ,  Peter Andrew Seubert ,  Russell E. Rydel

IPC分类号： A01K067/00

CPC分类号： C07K14/4711 ,  A01K67/0275 ,  A01K67/0276 ,  A01K67/0278 ,  A01K2207/15 ,  A01K2217/00 ,  A01K2217/05 ,  A01K2217/075 ,  A01K2227/00 ,  A01K2267/0312 ,  A01K2267/0356 ,  C07K2319/02 ,  C12N15/8509

摘要： The construction of transgenic animal models of human Alzheimer'disease, and methods of using the models to screen potential Alzheimer's disease therapeutics, are described. The models are characterized by pathologies similar to pathologies observed in Alzheimer's disease, based on expression of all three forms of the null-amyloid precursor protein (APP), APP695, APP751, and APP770, as well as various point mutations based on naturally occurring mutations, such as the London and Indiana familial Alzheimer's disease (FAD) mutations at amino acid 717, predicted mutations in the APP gene, and truncated forms of APP that contain the Anull region. Animal cells can be isolated from the transgenic animals or prepared using the same constructs with standard techniques such as lipofection or electroporation. The transgenic animals, or animal cells, are used to screen for compounds altering the pathological course of Alzheimer's disease as measured by their effect on the amount of APP, null-amyloid peptide, and numerous other Alzheimer's disease markers in the animals, the neuropathology of the animals, as well as by behavioral alterations in the animals.

摘要翻译： 描述了人类阿尔茨海默病的转基因动物模型的构建以及使用该模型筛选潜在的阿尔茨海默病治疗剂的方法。 基于所有三种形式的β-淀粉样蛋白前体蛋白（APP），APP695，APP751和APP770的表达以及基于天然存在的突变的各种点突变，模型的特征在于类似于在阿尔茨海默病中观察到的病理学的病理学 ，例如氨基酸717处的伦敦和印第安纳家族性阿尔茨海默病（FAD）突变，APP基因中预测的突变和含有Abeta区的APP的截短形式。 可以从转基因动物中分离动物细胞，或者使用具有标准技术如脂质转染或电穿孔的相同构建体来制备动物细胞。 转基因动物或动物细胞用于筛选改变阿尔茨海默氏病病理过程的化合物，如通过其对动物中APP，β-淀粉样蛋白肽和许多其他阿尔茨海默氏病标志物的量的影响所测量的，神经病理学 动物，以及动物的行为改变。

公开(公告)号：US20040194155A1

公开(公告)日：2004-09-30

申请号：US10678443

申请日：2003-10-01

申请人： GILEAD SCIENCES, INC.

发明人： William E. Delaney ,  Xiaofeng Xiong

IPC分类号： A01K067/00 ,  A01K067/033 ,  C12N015/00 ,  C12N015/09 ,  C12N015/63 ,  C12N015/70 ,  C12N015/74 ,  C12N005/00 ,  C12N005/02

CPC分类号： C07K14/005 ,  A61K38/00 ,  A61K39/00 ,  A61K2039/505 ,  C12N9/1276 ,  C12N2730/10122

摘要： Applicants have identified 5 mutants associated with hepatitis B virus resistance to adefovir, a nucleotide analogue antiviral drug widely employed in the therapy of hepatitis B. In accord with this invention, reverse transcriptase mutants rtN236T, rtA181V, rtA181T and their corresponding surface antigen mutants sL173F and sL172trunc are provided. The mutant proteins, antibodies thereto and nucleic acids encoding the mutants have diagnostic value in monitoring and adjusting patient therapy with adefovir and in the therapy of patients infected with the mutants.

摘要翻译： 申请人已经确定了与乙型肝炎病毒抗性相关的5种突变体，阿德福韦，广泛用于乙型肝炎治疗的核苷酸类似物抗病毒药物。根据本发明，逆转录酶突变体rtN236T，rtA181V，rtA181T及其相应的表面抗原突变体sL173F和 提供sL172trunc。 突变蛋白，其抗体和编码突变体的核酸在监测和调整阿德福韦的患者治疗以及感染突变体的患者的治疗方面具有诊断价值。

公开(公告)号：US20040191763A1

公开(公告)日：2004-09-30

申请号：US10678454

申请日：2003-10-01

申请人： GILEAD SCIENCES, INC.

发明人： William E. Delaney ,  Xiaofeng Xiong

IPC分类号： C12Q001/70 ,  A01K067/00 ,  C07H021/04 ,  C12N007/00 ,  C07K014/02 ,  C12N015/86

CPC分类号： C07K14/005 ,  A61K38/00 ,  A61K39/00 ,  A61K2039/505 ,  C12N9/1276 ,  C12N2730/10122

摘要： Applicants have identified 5 mutants associated with hepatitis B virus resistance to adefovir, a nucleotide analogue antiviral drug widely employed in the therapy of hepatitis B. In accord with this invention, reverse transcriptase mutants rtN236T, rtA181V, rtA181T and their corresponding surface antigen mutants sL173F and sL172trunc are provided. The mutant proteins, antibodies thereto and nucleic acids encoding the mutants have diagnostic value in monitoring and adjusting patient therapy with adefovir and in the therapy of patients infected with the mutants.

公开(公告)号：US20040177389A1

公开(公告)日：2004-09-09

申请号：US10465913

申请日：2004-04-12

发明人： David William Silversides ,  Maria Isabelle Daneau ,  Nicolas Pilon ,  Saffron C Dornan

IPC分类号： A01K067/00

CPC分类号： A01K67/0275 ,  A01K2217/05

摘要： Methods for controlling sex determination in non-human mammals are provided, including constructs for the production of transgenic mammals and the non-human transgenic mammals themselves.

摘要翻译： 提供了用于控制非人哺乳动物性别测定的方法，包括用于生产转基因哺乳动物和非人转基因哺乳动物本身的构建体。